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Embryonic Stem (ES) cells can give rise, in vivo, to the ectodermal, endodermal and 
mesodermal germ layers and, in vitro, can differentiate into multiple cell lineages, offering 
broad perspectives in regenerative medicine. Understanding the molecular mechanisms 
governing ES cell commitment is an essential challenge in this field. The Mitogen Activated 
Protein Kinase (MAPK) pathways, ERK, JNK and p38MAPK, are able to regulate ES 
commitment from early steps of the process to mature differentiated cells. Whereas the ERK 
pathway inhibits the self-renewal of ES cells, upon commitment this pathway is involved in 
the development of extraembryonic tissues, in early mesoderm differentiation and in the 
formation of mature adipocytes; p38MAPK displays a large spectrum of action from neurons 
to adipocytes and JNK is involved in both ectoderm and primitive endoderm differentiations. 
Furthermore, for a given pathway, several of these effects are isoform-dependent, revealing 
the complexity of the cellular response to activation of MAPK pathways. Regarding tissue 
regeneration, the potential outcome of systematic analysis of the function of different MAPKs 




ES cells can give rise, in vivo, to the ectodermal, endodermal and mesodermal germ 
layers and, in vitro, can differentiate into multiple cell lineages, offering broad perspectives in 
regenerative medicine (see for extensive reviews on mouse and human ES cells [1] and [2]). 
One existing limitation to the therapeutical use of these cells is that, in vitro, the capacity to 
orientate ES cells in a given lineage is often limited to a small proportion of cells. In fact, the 
cellular population obtained is usually a mixture of different specialized cells. Thus, 
understanding the molecular mechanisms governing commitment of ES cell to specific 
lineages is an essential challenge in this field. 
Mouse ES cells can be maintained, in vitro, in an undifferentiated state in the presence 
of a cytokine, the leukaemia inhibitory factor (LIF) [3, 4]. Mouse ES cell self-renewal is 
dependent on: i) intracellular pathways initiated by LIF and by either serum or Bone 
Morphogenetic Protein 2 or 4 (BMP2 or 4), ii) activity of transcription factors involved in the 
development of the embryo: Oct4, Nanog, Sox2 and FoxD3 [5]. Removing LIF and adding 
appropriate differentiation reagents result in the commitment of ES cells into a variety of 
mature differentiated cell types (see [6] and [1] for reviews). Straight-forward synthesis of the 
literature regarding ES cell differentiation is hindered by the widely-varied deployment of 
differentiation protocols (embryoid bodies, attached ES cells, etc ...) that lack or include fetal 
bovine serum and the use of specific inducers such as retinoic acid (RA). While neural 
differentiation of ES cells is apparently a default program [7], this differentiation program is 
markedly enhanced by incubation with RA and/or differentiation in serum-free media [8] [9, 
10]. By contrast, ES cell differentiation in the presence of fetal bovine serum, but the absence 
of RA, yields efficient differentiation to cardiomyocytes with few neurons [9, 11]. It is almost 
certain that different differentiation protocols and inducers will selectively activate distinct 
signalling pathways that activate cell lineage-specific genetic programs to bring about the 
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observed enrichment in differentiated cell populations. Yet, the precise molecular identity of 
these signalling pathways controlling cell differentiation of ES cells remains poorly 
understood. The purpose of this article is to review the recent studies that identify the role of 
Mitogen Activated Protein Kinases (MAPKs) in the in vitro differentiation of ES cells.  
 
The MAP Kinase signal transduction pathways 
Cells respond to extracellular signals by engaging a variety of intracellular 
signalling pathways, which trigger both immediate and long-term cell responses. The latter 
activate cascades that signal to the nucleus and regulate gene expression. The signalling 
pathways leading to activation of mitogen-activated protein kinases (MAPKs) and their 
downstream effects on gene regulation represent a paradigm in cellular signalling (see 
reviews [12, 13]). The MAPK family comprise four groups of proteins: extracellular signal-
regulated kinases (ERKs) 1 and 2; ERK5; c-Jun amino-terminal kinases (JNKs) 1, 2 and 3; 
and p38MAPK , and  where each isoform is encoded by its own gene. Much of the 
present understandings of the MAPKs, especially regarding ES cell signalling, arise from the 
study of ERK1/2, JNK and p38MAPK proteins. These protein serine/threonine kinases are 
regulated by phosphorylation cascades organized in specific modules comprised of two 
additional protein kinases activated in series and leading to activation of a specific MAP 
Kinase: a MAP Kinase Kinase (MAPKK), which phosphorylates a specific MAPK, and a 
MAP Kinase Kinase Kinase (MAPKKK), which phosphorylates a specific MAPKK (Figure 
1). Besides the activities of the different components of the cascades themselves, there are 
two others important means to specifically regulate these signalling pathways: interfering with 
the scaffolding proteins or MAPK phosphatases that are specific for each pathway.  
Taking advantage of the development of specific chemical inhibitors for each MAPK 
pathway, numerous investigations have explored their biological functions and demonstrated 
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their involvement in a wide variety of cellular functions. These multiple functions are 
dependent on the pathway that is activated and on the cellular model analysed. In addition, the 
duration of the stimulus can also affect the cellular response. A wide panel of different stimuli 
are able to activate the MAPK pathways, but a good correlation has been found between the 
types of stimulus and the function assigned to the pathway. Schematically, ERK is 
preferentially activated by mitogens such as the serum or growth factors and, accordingly, this 
pathway is an important regulator of cell cycle and cell proliferation; whereas p38MAPK and 
JNK are responsive to various stress stimuli from UV to cytokines, and constitute important 
mediators of cellular responses to these stimuli (see for extensive reviews [14] and [12]; and 
more recently: [15], [16] and [17]). For example, the JNK pathway is the mediator of 
apoptosis induced by TNF-However, this growth factor is also able to activate the NF-B 
pathway, which, in turn, inhibits JNK. Therefore the cellular response will result from the 
combinatorial action of distinct signalling pathways.  
Regarding the process of differentiation, the role of MAPKs is extremely complex and 
depends on multiple parameters. The complexity is due, firstly, to the biological process itself, 
which, in general, involves distinct, successive steps. Furthermore, each of these steps can be 
modulated by MAPKs leading, sometimes, to opposite effects. Probably because of this 
complexity, most of the tools used for these studies have found their limitations. With regard 
to small molecule inhibitors of protein kinases, inhibitors of a given pathway differ widely in 
their inhibitory potency and specificity [18]. Therefore, interfering with a given pathway with 
chemical inhibitors can induce different biological effects by virtue of simple non-specific 
effects. Alternatively, investigators have constructed cell lines from various cellular models, 
overexpressing dominant-negative or activated forms of the genes encoding the components 
of MAPK pathways. While often informative, these experiments are not totally conclusive 
because of the complexity of the differentiation process and the possible cross talk between 
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the different pathways in such conditions. Finally, homozygous knockouts of several 
components of MAPK pathways are now available, both in vivo, in mice, and in vitro, in ES 
cell lines [19]. Whereas targeted gene disruption in animals may unveil important biological 
functions, they also have limits, especially when the knock-out is lethal during early 
embryogenesis. Recently, the study of ES cells bearing disrupted MAPK genes revealed that: 
no role could been assigned to these pathways in undifferentiated ES cells as MAPK 
pathways are apparently dispensable for ES cell self-renewal and cell cycle (see below). By 
contrast, new biological functions can be attributed to these proteins in the modulation of ES 
cell lineage commitment, which is the subject of the subsequent sections of this review. 
 
The ERK pathway 
Engagement of the gp130 cytokine receptor subunit by the LIF generates two 
intracellular signalling pathways: on one hand, the JAK-STAT3 pathway, which is required 
for ES self-renewal, and, on the other hand, the ERK pathway. Surprisingly and in contrast to 
most cultured cell lines, undifferentiated ES cells do not require the ERK pathway for normal 
cell cycle, proliferation and self-renewal [20-22]. In fact, inhibition of this pathway actually 
promotes self-renewal of murine ES cells. These observations are in agreement with the study 
of K-Ras
-/-
 ES cells, the absence of this gene leading to downregulation of the ERK pathway. 
These cells display LIF-independent capacity to grow undifferentiated [23]. Therefore, it 
appears that the self-renewal signal downstream of LIF is a finely tuned balance of positive 
(via STAT3 proteins) and negative (via the ERK pathway) effectors [24]. 
The dominant role of the ERK pathway becomes apparent upon differentiation, 
both in vivo and in vitro. Interfering with the ERK signalling pathway, for example by knock-
out of the upstream activator Grb2, leads to inhibition of primitive endoderm [25, 26] and 
trophectoderm formations [27]. These in vivo observations have also been reproduced in 
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cultures of the corresponding deficient ES cells. Surprisingly, activation of the ERK pathway 
by an oncogenic Ras also interferes with extraembryonic endoderm differentiation of 
embryonic stem cells [28]. It is likely that a critical level of activation of the ERK pathway is 
necessary for this early commitment and that up or down variations of this threshold level 
have deleterious consequences. Beside these early functions in commitment, not much was 
known about the role of ERK in ES cell differentiation. Recently, our laboratory showed that 
the treatment of ES cells by retinoic acid, which is required for induction of neurogenesis and 
adipogenesis, activates the ERK pathway. Inhibition of ERK activation, using specific 
chemical inhibitors during this period, results in a strong inhibition of adipocyte formation 
without affecting neurogenesis [29]. Furthermore, by studying knock-out animals and 
fibroblasts, the role of ERK in adipogenesis appears to be limited to ERK1, with no role for 
ERK2 in this process [30]. To gain genetic evidence of the role of ERK1 in adipocyte 
differentiation of ES cells and to analyse its function in other cell lineages, it would be of 
interest to generate and test the differentiation capacities of ERK1
-/-
 ES cells. 
Interestingly, while ERK1
-/-
 mice are viable and fertile [31], disruption of ERK2 is 
embryonic lethal due to defective placenta formation, trophectoderm and mesoderm 
differentiations [32, 33]. These findings confirm the direct role of the ERK pathway early 
during the embryonic development. Furthermore, they demonstrateERK1 and ERK2 have 
distinct biological functions. While, as expected, ERK2 disruption does not interfere with 
proliferation of undifferentiated ES cells, no apparent mesoderm-derived lineages can be 
observed upon ES commitment (B. Binetruy and F. Bost, personal observation), suggesting 
that ERK2 is necessary at an early step of ES cell commitment. Since ERK
-/-
mice present 
normal mesoderm differentiation -except for adipocyte formation-, it is likely that the defect 
of ERK2
-/-
 ES cells in mesoderm commitment takes place earlier than the defective 
adipogenesis of ERK1
-/-
 cells.  
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Many defined ERK substrates are transcriptional regulators (reviewed in [34]), but 
what specific molecular mechanisms are controlled by each of the ERK isoforms during 
mesoderm formation remains to be determined. Regarding adipocyte differentiation, the 
positive role of the ERK pathway is blurred by works demonstrating that the adipocyte-
specific transcription factor PPAR is a substrate of ERK and that this phosphorylation 
decreases its transcriptional activity and inhibits adipocyte differentiation [35, 36]. Owing to 
the known role of ERK in cell proliferation, one could reconcile these contradictory results by 
hypothesizing that the function of ERK in adipogenesis is dictated by the window of time 
during which it is activated. Early in the program, ERK activity is increased for a proliferative 
step, while later, it must be inactivated to prevent PPAR phosphorylation. This model is 
supported by the fact that the expression of MKP-1, the phosphatase that inhibits ERK, is 
augmented in mature adipocytes [37]. 
 
The p38MAPK pathway 
Among the four p38MAPK isoforms, , and only the knock-out of p38 is 
embryonic lethal [38], the others presenting no apparent phenotype. The lethality is due to 
both embryonic defect and a lack of erythropoietin expression. It has been shown that the 
p38MAPK pathway plays a crucial role during early mammalian somite development and 
myotome formation, at E9.5 of the embryo development, by signaling to the MEF2 
transcriptional regulators [39]. The p38 isoform is the only one expressed in ES cells [40]. 
Whereas no role has been assigned to p38MAPK in undifferentiated ES cells, p38MAPK 
activation is involved in the early apoptosis observed in a fraction of ES cells early on upon 
induction of differentiation [41]. Although p38MAPK protein expression is constant, two 
waves of p38MAPK activity characterise the ES cell differentiation process, one between day 
2 to 5 [11, 41] and one, latter on, between day 12 to 16 [42]. By analysing both the effects of 
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p38MAPK-specific pharmaceutical inhibitors and the in vitro differentiation capacities of ES 
cells deficient for the p38 gene, our laboratory found that these activities regulate ES cell 
commitment. The early peak of P38MAPK activity controls a switch between 
cardiomyogenesis (p38MAPK activity turned on) and neurogenesis (p38MAPK off) [11], 
while the second one inhibits adipogenesis [42]. 
Interestingly, RA treatment inhibited both the first peak of p38MAPK activation and the 
in vitro formation of cardiomyocytes. Therefore, it is likely that RA blocks cardiomyogenesis 
in ES cells via p38MAPK inhibition. Few studies have shown that RA modulates MAPK 
activity, however, a recent report demonstrated that RA inhibits cyclic stretch induced activity 
in neonatal cardiomyocytes via MAPK inhibition [43]. This inhibition could be due to an 
increase of expression of the MAPK phosphatases MKP-1 and -2 by RA. Either deletion of 
p38MAPK or specific inhibition of its peak of activity partially mimicked the in vitro RA 
inhibition of cardiomyogenesis and reduced expression of cardiomyocyte markers, including 
the important transcription factorMEF2C [11], which acts on many genes encoding cardiac 
structural proteins. Interestingly, p38MAPK is a well-known regulator of MEF2C [44-47], 
suggesting that the p38MAPK effect could be directly due to MEF2C regulation. Consistent 
with this hypothesis, a role for p38 in various aspects of cardiomyogenesis including the 
regulation of cardiomyocyte differentiation, apoptosis, and hypertrophy has been described 
[48-50], and, accordingly, p38-/- embryos present a massive reduction of the myocardiac 
muscle attributed to a defect in placental development [51]. 
In PC12 and P19 cell lines, p38MAPK activation is required for neurite formation and 
neuron survival during late stages of differentiation [52, 53]. In fact, the role of p38MAPK in 
these cells is restricted to the late stages of differentiation. Indeed, PC12 cells are already 
committed into the neuronal lineage [54] and P19 is a multipotent embryonic cell line [55, 56] 
that terminally differentiates into neurons after RA treatment. By contrast, analysis of the role 
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of p38MAPK in the early stages of neuron differentiation, during ES cells commitment, 
revealed an opposite function for this kinase. Inhibition of p38MAPK using specific inhibitors 
or p38-/- cells is sufficient to induce, spontaneously, a high level of neurogenesis [11]. 
Altogether these results suggest that p38MAPK may exert different roles depending on 
the stage of neuronal differentiation: inhibitory during cell commitment and anti-apoptotic 
during the late stages of differentiation. It is very likely that the molecular mechanisms 
underlying these distinct functions are different and their identification should be of a great 
interest for the development of ES cells in therapeutic applications.  
 
The JNK pathway 





 mice undergo mid-gestational embryonic lethality associated with defects in neural tube 
closure and deregulated neural apoptosis [57, 58]. The deletion of JNK1, but not JNK2, leads 
to the resistance to high-fat diet induced obesity and the absence of JNK1 leads to a better 
insulin sensitivity attributed to a reduced phosphorylation of IRS-1 on Ser307 [59]. However, 
if the JNK pathway is involved in insulin signalling, there is no evidence for a role of this 
pathway in adipocyte differentiation. Similar to the ERK and p38 MAPK pathways, the JNK 
family of MAPKs are not required for self-renewal or maintenance of ES cells [8]. A variety 
of approaches have defined a role for the JNK pathway in differentiation of ES cells as well as 
P19 embryonal carcinoma cells to neural and extraembryonic endoderm lineages. We recently 
employed ES cells derived from mice bearing disrupted jnk1, jnk2 or jnk3 to define a 
requirement for JNK1 in retinoic acid-induced neurogenesis [8]. Importantly, the lack of 
neurogenesis by JNK1
-/-
 ES cells was associated with enhanced induction of an epithelial 
differentiation program evidenced by increased E-cadherin. In addition, the expression of 
Wnt-4, Wnt-6 and BMP4 were markedly increased in the JNK1
-/-
 cultures, consistent with a 
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role for specific Wnts and BMP4 as members of a key lineage commitment switch in ES cell 
differentiation [60] [61] [7]. A role for the JNKs in neural differentiation of ES cells is 
consistent with the observation of similarly reduced neural differentiation in ES cells deficient 
for the JNK pathway scaffold protein, JSAP [62]. Thus, these studies support a model where 
JNK1 activity represses a Wnt-4/Wnt-6 and BMP4 signaling axis that would otherwise direct 
the cells towards an epithelial lineage. 
The earliest two extraembryonic cell lineages are the trophectoderm and the primitive 
endoderm, which will form the placenta and yolk sac, respectively. Following implantation of 
early mammalian embryos, primitive endoderm differentiates to visceral endoderm and 
parietal endoderm; these tissues reside on the periphery of embryoid bodies formed in vitro by 
ES cells and embryonal carcinoma cells. Several groups have used P19 cells to unveil the 
requirement of a JNK signalling pathway in the retinoic acid-stimulated differentiation of 
these cells to primitive endoderm lineages [63]. In addition, our own recent studies reveal that 
retinoic acid-stimulated expression of a variety of visceral and parietal endoderm lineage 
markers (GATA4, GATA6, Sox17, disabled 2, -fetoprotein) are inhibited in JNK1-/- and 
JNK2
-/-
 ES cell-derived embryoid bodies (L. Heasley, unpublished observation). In the P19 
cell model system, signaling by the heterotrimeric G protein, G13, and stimulation of the 
activity of p115RhoGEF is required for primitive endoderm differentiation [64]. Moreover, a 
recent study by Kashef et al [65] demonstrated that the G13-interacting JNK pathway scaffold 
protein, JLP, is markedly induced by retinoic acid in P19 cells. Thus, a key regulatory step in 
retinoic acid-stimulated primitive endoderm differentiation appears to be the increased 
expression of a specific scaffold protein to assemble a G13-stimulated JNK module. 
 
Conclusions and perspective 
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MAPK pathways are able to regulate both the early embryonic development and the ES 
cell commitment from early steps of the process to mature differentiated cells (the various 
effects are summarised in Figure 2). The ERK pathway is mainly involved in mesoderm 
differentiation, especially in adipogenesis, with both positive and negative effects. p38MAPK 
displays a large spectrum of action from neurons to adipocytes and JNK is involved in both 
ectoderm and primitive endoderm differentiations. Furthermore, for a given pathway, these 
effects are isoform-dependent, revealing the complexity of the cellular response to activation 
of these pathways. Notably, several lineages tested are affected by more than one transduction 
pathway. Adipogenesis is controlled by both ERK and p38MAPK and neurogenesis is 
controlled by both p38MAPK and JNK. These observations are reminiscent of our recent 
studies in PC12 pheochromocytoma cells, indicating that complex differentiation programs 
such as neurogenesis will involve the integration of multiple signal pathways [66]. Even the 
induction of a neural-specific gene such as neurofilament light chain in these cells involves 
the concerted action of the ERK and JNK signal pathways [66]. Thus, it is equally likely that 
distinct ES cell lineage commitment programs will be regulated through the integrated action 
of two or more MAPK families. Cross talks between MAPK pathways can be either 
synergistic -ERK/JNK in neural differentiation of PC12- or antagonistic -p38MAPK/ERK in 
adipocyte differentiation of ES cells. Yet, taking advantage of the availability of the various 
MAPKs-disrupted ES cell lines, the role of MAPKs in differentiation of numerous other cell 
types needs to be investigated. 
Altough the precise molecular mechanisms underlying the various MAPK functions in 
ES cell commitment are unknown, they must eventually lead to activation of cell lineages-
specific genetic programs. Recently, important features of regulation of gene expression in ES 
cells have been unveiled. In undifferentiated mouse and human ES cells, the transcriptional 
repressors Polycomb Group proteins (PcG) repress numerous developmental regulators that, 
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once de-repressed, are able to trigger ES cells to undergo differentiation [67-69]. The 
repression is due to the PcG-induced hypermethylation of histone proteins in nucleosomes 
occupying key-regions of the gene promoters. Upon induction of differentiation this process is 
reverted and developmental regulators are expressed. These results underline the critical role of 
chromatin modification in ES cell commitment. Interestingly, MAPKs induce a dynamic 
change in histone phosphoacetylation during ES cell differentiation [70]. Yet, we do not know 
whether this regulation is related to the biological role of MAPKs in ES cell commitment. 
Dominant signal pathways that control ES cell lineage commitment in vitro do not 
always translate to critical roles for these MAPK pathways unveiled with gene knockout 
approaches during mouse development. As an example, JNK1-deficient ES cells fail to 
undergo neurogenesis [8]. Yet, the JNK1 knockout mouse develops normally. Also, our own 
studies (L. Heasley, unpublished observations) reveal inhibited extraembryonic endoderm 
differentiation by ES cells deficient for either JNK1 or JNK2. Yet, marked perturbations in 
extraembryonic endoderm fate specification is not observed, even in embryos lacking both 
JNK1 and JNK2. The implication from these discrepancies is that studies of signal 
transduction in ES cells will not always provide information that directly transfers to mouse 
development. One potential outcome of systematic analysis of the function of different 
MAPKs in different ES cell differentiation programs is that inhibitors to specific protein 
kinases may be used to “trap” key cellular intermediates in ES cell lineage commitment 
pathways. These intermediate cell types may serve as more useful reagents for tissue 
regeneration in vivo than the fully differentiated cell types. Obviously, a progenitor may be 
more likely to reconstitute multiple cell types within a tissue relative to a more differentiated 
cell type. Since the ultimate goal of tissue regeneration is the use of in vitro committed stem 
cells, it is crucial to understand and control the various steps of their differentiation. The 
pharmacological regulation of MAP Kinase activities could participate in the obtaining of 
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such cells. Furthermore, this strategy could be extended to other protein kinase families. 
Finally, whereas this review focuses on mouse ES cells, the role of signal transduction 
pathways and of MAP Kinases, in particular, in human ES cell differentiation is still largely 
unexplored. Interestingly, and by contrast to mouse ES cells, a recent work indicates that ERK 
could be necessary for the maintenance of human ES cell pluripotency [71]. 
In conclusion, despite the fact that not all ES cell findings may directly translate to 
dominant mechanisms of cell fate specification during development, they provide a highly 
valuable foundation of knowledge as tissue propagation from ES cells emerges as a discipline 
distinct from developmental biology. 
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Legends to figures 
 
Figure 1 
Schematic representation of the main MAP Kinase signal transduction pathways 
and their regulators. 
 
Figure 2 
Proposed model for the in vivo and in vitro MAPK effects on development (in 
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